University of Chicago Medicine researchers have built a model system that uses multiple cell types from patients to rapidly test compounds that could block the early steps in ovarian cancer metastasis. Their three-dimensional cell-culture system, adapted for high-throughput screening, has enabled them to identify small molecules that can inhibit adhesion and invasion, preventing ovarian cancers from spreading to nearby tissues.
The study, published online February 5, 2015, in the journal Nature Communications, is the first to describe a high-throughput screening drug-discovery platform for ovarian cancer that mimics the structural organization and function of human tissue. The model reconstructs the surfaces of the omentum and the peritoneum, membranes that line the abdominal cavity, which are the most frequent sites of ovarian cancer metastasis.
This is a multi-layered 3-D 'organotypic' platform for quantitative high-throughput screening to identify new therapeutics for ovarian cancer. Fibroblasts are red. Mesothelial cells are blue. Ovarian cancer cells are green. The square image is the XY-planes (up-down, right-left). The images on the sides are Z-planes (depth).
Credit: Lengyel laboratory, University of Chicago
"Visualizing how cancer cells interact with a tumor microenvironment that accurately reflects the complex biology of ovarian cancer should help us understand the mechanisms underlying metastatic progression as well as identify new therapeutics that can inhibit this process," said clinical gynecologic oncologist Ernst Lengyel, MD, PhD, senior author of the study and a professor of obstetrics and gynecology at the University of Chicago.
This is a long overdue step forward for ovarian cancer therapy. The current treatment for metastatic ovarian cancer is surgery and chemotherapy, which has a low five-year survival rate. Although recently approved therapies can increase progression-free survival by a few months, "we think this novel screening system has the potential to uncover new, more effective medications that could be targeted more specifically at a patient's cancer," Lengyel said.
Each year about 21,290 women in the United States will be diagnosed with ovarian cancer and about 14,180 women will die from the disease. Ovarian cancer is aggressive and is rarely detected at an early stage. Tumors that form in the ovary or fallopian tube typically travel through the peritoneal fluid to the surfaces of other abdominal organs. Metastatic tumors are usually confined to the abdominal cavity and initially cause few symptoms.
To assemble their model, the researchers collected non-cancerous omental tissue from patients undergoing abdominal surgery. In the laboratory, they isolated and cultured mesothelial cells and fibroblasts, two of the predominant cell types found in omental tissue. Then they combined these cells with extracellular matrix proteins to generate a multi-layered cell-culture model.
The authors were able to miniaturize their model for use in high-throughput screening (HTS), a drug discovery process that can quickly determine the biological or biochemical activity of thousands of compounds. Because HTS has traditionally been performed on an unrealistic platform--monolayers of cancer cells cultured on plastic surfaces--many drugs that seemed promising in initial screens proved ineffective in clinical testing.
So the researchers developed a new system that better reflects human biology and is specific to ovarian cancer. Instead of growing cancer cells on plastic, they inserted a multi-layered omental tissue culture model into each well of a 384-well or 1536-well HTS platform.
Next, ovarian cancer cells, expressing a fluorescent marker to distinguish them from the other cells, were added. Then the wells were exposed to a library of small-molecule compounds. The numbers of ovarian cancer cells that adhered to and invaded the HTS model were counted, and the inhibitory potential of each compound evaluated.
In a primary screen, the researchers identified 17 compounds that inhibited cancer cell adhesion and invasion by at least 75 percent. Six of these compounds were active in a dose-response relationship in three distinct ovarian cancer cell lines. Four compounds significantly inhibited key ovarian cancer cell functions in the early steps of metastasis at low doses.
The research team confirmed those results by testing the four compounds at a low dose in mice injected with ovarian cancer cells. Remarkably, all four compounds inhibited metastasis. Two compounds more than doubled survival. In a follow-up study, one of the compounds--beta-escin, isolated from the seed of the Chinese horse chestnut--inhibited tumor growth and metastasis by 97 percent.
"This study was based on our initial tests of 2,420 compounds," said first author Hilary Kenny, PhD, a research associate (assistant professor) in obstetrics and gynecology at the University of Chicago. "Our model has since been used to test more than 68,000 compounds. This could exceed 100,000 by the end of this year. We are learning to identify compounds with similar structures and functions that may be important for inhibiting key steps in metastasis."
This project emerged as a result of the patient-oriented approach taken by the researchers and clinicians. It is "an important step towards personalized medicine, as described in the new precision medicine initiative proposed by President Obama," Kenny said. "In the future, organotypic models that reflect the unique biology of individual patients could be used in screening. Therefore, personalized high-throughput screening platforms could enable the identification of effective therapeutics for each patient. This is exactly how personalized medicine is supposed to work."
The study was funded by Bears Care, the charitable beneficiary of the Chicago Bears Football Club; the National Institutes of Health; the National Cancer Institute; and the National Institute of Neurological Disorders and Stroke. Additional authors were Erin A. White, Chun-Yi Chiang, Anirban K. Mitra, Yilin Zhang, Marion Curtis, Elizabeth M. Schryver and Sam Bettis from the University of Chicago; and Ajit Jadhav, Matthew B. Boxer, Madhu Lal-Nag, Min Shen, Zhuyin Li, and Marc Ferrer from the NIH's National Center for Advancing Translational Sciences.
John Easton | EurekAlert!
The end of pneumonia? New vaccine offers hope
23.10.2017 | University at Buffalo
Scientists track ovarian cancers to site of origin: Fallopian tubes
23.10.2017 | Johns Hopkins Medicine
Salmonellae are dangerous pathogens that enter the body via contaminated food and can cause severe infections. But these bacteria are also known to target...
University of Maryland researchers contribute to historic detection of gravitational waves and light created by event
On August 17, 2017, at 12:41:04 UTC, scientists made the first direct observation of a merger between two neutron stars--the dense, collapsed cores that remain...
Seven new papers describe the first-ever detection of light from a gravitational wave source. The event, caused by two neutron stars colliding and merging together, was dubbed GW170817 because it sent ripples through space-time that reached Earth on 2017 August 17. Around the world, hundreds of excited astronomers mobilized quickly and were able to observe the event using numerous telescopes, providing a wealth of new data.
Previous detections of gravitational waves have all involved the merger of two black holes, a feat that won the 2017 Nobel Prize in Physics earlier this month....
Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).
When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...
Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.
How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...
23.10.2017 | Event News
17.10.2017 | Event News
10.10.2017 | Event News
23.10.2017 | Life Sciences
23.10.2017 | Physics and Astronomy
23.10.2017 | Health and Medicine